HFpEF患者肾功能与电解质指标访间变异性与不良结局的关联
该队列分析基于TOPCAT试验数据,纳入2479至3195例有≥3次连续实验室检测的HFpEF患者,评估前4个月内肾功能(肌酐、BUN)和电解质(钠、氯、钾)的访间变异性与主要复合终点及全因死亡的关系。结果显示BUN、肌酐、钠和钾的变异性独立关联于更高的主要复合终点风险,且肾功能变异性的关联在CKD亚组及不同治疗臂中一致。
要点
- HFpEF患者肾功能和电解质指标的访间变异性常见,且与长期不良结局独立相关。
- BUN和肌酐变异性越高,主要复合终点和死亡风险越高。
- 钠和钾变异性亦与主要复合事件风险升高显著相关。
核心结论
- HFpEF患者肾功能和血清电解质指标的访间变异性普遍存在,且独立关联于更差的长期临床结局。
研究设计与样本
- 基于TOPCAT试验数据的队列分析,纳入有3次及以上连续实验室检测且在入组后4个月内无事件的患者,共分析2479例(BUN)至3195例(钾)。
主要发现
- BUN每升高1-SD的ASV,主要复合终点风险HR为1.21(95%CI 1.10-1.33);肌酐每升高1-SD的ASV,HR为1.13(95%CI 1.04-1.22)。
- 钠每升高1-SD的ASV,主要复合事件HR为1.14(95%CI 1.01-1.30);钾每升高1-SD的ASV,HR为1.21(95%CI 1.02-1.44)。
- 肾功能变异性的关联在CKD亚组(HR 1.39,95%CI 1.16-1.67)和无CKD亚组(HR 1.13,95%CI 1.01-1.27)中一致。
- 肾功能变异性的关联在螺内酯组(HR 1.30,95%CI 1.03-1.65)和安慰剂组(HR 1.27,95%CI 1.04-1.56)中分别显著。
临床怎么用
- 在HFpEF长期管理中,可关注肾功能和电解质指标的访间波动,作为风险分层参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although kidney dysfunction and abnormalities in serum electrolyte levels are associated with poor clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF), the association of visit-to-visit variability in such laboratory measures with long-term outcomes is unclear. OBJECTIVE: To evaluate the associations of visit-to-visit variability in indexes of kidney function (creatinine and blood urea nitrogen [BUN] levels) and serum electrolyte (sodium, chloride, and potassium) with the risk of adverse clinical outcomes among patients with chronic, stable HFpEF. DESIGN, SETTING, AND PARTICIPANTS: This cohort analysis used data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. All participants with 3 or more serial laboratory measurements who were event free within the first 4 months of enrollment were included. Data were analyzed from March 1, 2019, to January 31, 2020. MAIN OUTCOMES AND MEASURES: Adjusted associations between indexes of variability in serum laboratory measurements during the first 4 months of follow-up and risk of the primary composite outcome (a composite of aborted cardiac arrest, hospitalization for heart failure, or cardiovascular death) and all-cause mortality were assessed using Cox proportional hazards regression models. RESULTS: Of the 3445 patients enrolled in the TOPCAT trial (mean [SD] age, 68-69 [10] years; 49.7%-51.5% female), 2479 (BUN) to 3195 (potassium) were analyzed, depending on availability of serial measurements. Participants with higher laboratory variability in kidney function parameters were older, had more comorbidities, and had more severe symptoms of HFpEF. Higher visit-to-visit variability in BUN (hazard ratio [HR] per 1-SD higher average successive variability [ASV], 1.21; 95% CI, 1.10-1.33) and creatinine (HR per 1-SD higher ASV, 1.13; 95% CI, 1.04-1.22) were independently associated with a higher risk of the primary composite outcome as well as mortality independent of other baseline confounders, changes in kidney function, changes in medication dosages, and variability in other cardiometabolic parameters (systolic blood pressure and body mass index). The higher risk associated with greater variability in kidney function was consistent across subgroups of patients stratified by the presence of chronic kidney disease (CKD) at baseline (CKD: HR per 1-SD higher ASV, 1.39; 95% CI, 1.16-1.67 and no CKD: HR per 1-SD higher ASV, 1.13; 95% CI, 1.01-1.27), among placebo and spironolactone treatment arms separately (spironolactone arm: 1.30; 95% CI, 1.03-1.65 and placebo arm: HR per 1-SD higher ASV, 1.27; 95% CI, 1.04-1.56). Among serum electrolytes, variability in sodium and potassium measures were also significantly associated with a higher risk of primary composite events (sodium: HR per 1-SD higher ASV, 1.14; 95% CI, 1.01-1.30 and potassium: HR per 1-SD higher ASV, 1.21; 95% CI, 1.02-1.44). CONCLUSIONS AND RELEVANCE: In HFpEF, visit-to-visit variability in laboratory indexes of kidney function and serum electrolytes is common and independently associated with worse long-term clinical outcomes.
引用
- Segar MW, Patel RB, Patel KV, et al. Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021. PMID: 33206129. doi:10.1001/jamacardio.2020.5592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。